Heidelberg University Hospital in Germany Invests in Fourth Accuray Radiotherapy Device, the Radixact® System, to Improve Cancer Patient Care
Accuray announced that Heidelberg University Hospital in Germany has opted to replace its existing TomoTherapy System with Accuray's Radixact System. The Radixact System will be outfitted with ClearRT, Synchrony, and VOLO Ultra Optimizer to improve the precision and speed of cancer treatment. This upgrade is intended to enhance the hospital's capacity to treat a wide range of cancer cases more effectively and efficiently. Heidelberg University Hospital, a well-regarded institution globally, is recognized for its excellence in patient care and groundbreaking research and has previously utilized Accuray's technologies to treat up to 100 patients per day.
- Heidelberg University Hospital invests in the Radixact System, indicating strong customer trust and satisfaction.
- Enhanced treatment capabilities with ClearRT, Synchrony, and VOLO Ultra Optimizer may lead to improved patient outcomes.
- Replacement of the older system suggests ongoing upgrades and commitment to cutting-edge technology.
- Potential for increased patient throughput and operational efficiency, treating up to 100 patients daily.
- No significant negative aspects reported in the press release.
Insights
The investment by Heidelberg University Hospital in the Radixact® System represents a significant step forward in their radiotherapy capabilities. The integration of ClearRT® for imaging, Synchrony® for motion tracking and the VOLO™ Ultra Optimizer for enhanced workflow collectively serve to improve the precision and speed of radiation treatments. This is important in treating complex cases where millimeter precision can make a significant difference in patient outcomes.
In the short term, this upgrade may result in increased patient throughput due to more efficient processes, potentially allowing the hospital to treat more patients daily. Over the long term, the enhanced image clarity and precision can lead to better patient outcomes, reinforcing the hospital’s reputation for excellence in cancer care.
From a clinical perspective, the transition to newer technology is likely to enhance the hospital's capability to manage a broader spectrum of cancer cases, including the most complex scenarios. This also aligns with the global trend of hospitals adopting advanced technologies to improve patient care and operational efficiency.
From a market perspective, Accuray's continued partnership with a leading institution like Heidelberg University Hospital reinforces their market position and could potentially influence other hospitals to consider adopting their technologies. The Radixact System's integration into such a high-profile hospital underscores its value and may serve as a strong endorsement.
For Accuray, this partnership could enhance their brand visibility and credibility, particularly in the European market, which is important for their growth. If Heidelberg University Hospital reports positive outcomes from using the Radixact System, it could serve as a powerful case study that Accuray can leverage in their marketing and sales efforts.
In the broader market context, this announcement might signal to investors that Accuray remains a competitive player in the radiotherapy equipment market, thus potentially influencing their stock performance positively in the long term.
- The Radixact System will be supplied with ClearRT®, Synchrony®, and the VOLO™ Ultra Optimizer to enhance radiation treatment delivery precision and speed
- Heidelberg University Hospital is recognized worldwide for excellence in patient care and practice changing research
"At Accuray, we understand that certainty matters - to the clinical teams that use our radiation therapy systems, the patients who undergo treatment and the families whose loved ones require care. That's why it's so important to our team to provide customers around the world with technology that enables them to treat a wider range of patients and feel confident they are offering the best possible option for a full, high-quality life," said Suzanne Winter, president and CEO of Accuray.
Continued Ms. Winter, "We are thrilled to continue our partnership with the Heidelberg University Hospital team, a global leader in cancer care. As long-term users of both Accuray radiotherapy delivery platforms they have a clear understanding of the value of the helical Radixact/TomoTherapy Systems' and industry-only robotic, stereotactic CyberKnife® System's unique designs. We look forward to supporting them as they embark on the next phase of providing advanced radiotherapy care for their patients."
Heidelberg University Hospital: Leveraging Advanced Equipment to Improve the Patient Experience
Heidelberg University Hospital was an early adopter of image-guided intensity modulated radiation therapy (IG-IMRT), a targeted form of external beam radiation therapy that uses images acquired before each treatment to help ensure accurate patient and tumor positioning before delivery of the radiation. Two TomoTherapy Systems enabled the hospital's team to treat up to 100 patients per day while leveraging the benefits of full image guidance made possible by IG-IMRT.
The Radixact System integrated with ClearRT helical fan-beam kVCT imaging, Synchrony motion tracking and synchronization technology, and VOLO Ultra Optimizer offers an enhanced workflow along with improved image clarity, enhanced precision, and the versatility necessary to treat more patients, better and faster. The hospital joins renowned facilities across
Heidelberg University Hospital has once again been named one of the best hospitals in the world in the latest edition of the "World's Best Hospitals 2024" ranking compiled by Newsweek magazine. Over their more than 100-year history, the hospital's center for radiation oncology has become one of the largest and most modern institutions around the globe, focusing on patient treatment as well as preclinical cancer research.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations regarding the benefits of the company's products to its customers; and patient experiences and patient outcomes. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 8, 2024, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/heidelberg-university-hospital-in-germany-invests-in-fourth-accuray-radiotherapy-device-the-radixact-system-to-improve-cancer-patient-care-302184128.html
SOURCE Accuray Incorporated
FAQ
What recent investment has Heidelberg University Hospital made in radiotherapy technology?
Why did Heidelberg University Hospital choose the Radixact System?
When was the announcement made about Heidelberg University Hospital's new investment in Accuray's Radixact System?
What are the components included in the Radixact System that Heidelberg University Hospital will use?
How does the Radixact System enhance patient care at Heidelberg University Hospital?
